Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance [Financial Post (Toronto, Ontario, Canada)]
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: Financial Post
PARIS, FRANCE, 23 October 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. Highlights Total-sales growth in the year to date of 9.2% at CER , or 8.1% as reported, with notable performances from Dysport (abobotulinumtoxinA), Cabometyx (cabozantinib) and Bylvay (odevixibat), with robust Somatuline (lanreotide) sales, as well as the increasing contribution from the launches of Iqirvo (elafibranor) in 2L PBC and Onivyde (irinotecan) in 1L mPDAC Regulatory approvals in the E.U. of Iqirvo and Kayfanda (odevixibat) Increased 2024 financial guidance: total-sales growth greater than 8.0% at CER (prior guidance: greater than 7.0% at CER ); core operating margin greater than 31.0% of total sales (prior guidance: greater than 30.0%) “Since the launch of our strategy in 2020, we have enjoyed uninterrupted growth. This quarter was no exception and was accompani
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)GlobeNewswire
- Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical TrialGlobeNewswire
- Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutions [Yahoo! Finance]Yahoo! Finance
ETON
Earnings
- 11/12/24 - Beat
ETON
Sec Filings
- 12/20/24 - Form 8-K
- 12/17/24 - Form 8-K
- 12/12/24 - Form 8-K
- ETON's page on the SEC website